First-line osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer

Epidermal growth factor receptor (EGFR) mutations, including exon 19 deletions and the point mutation L858R in exon 21, are found in 10–35% of non-small cell lung cancers (NSCLCs) and determine the treatment response to EGFR/tyrosine kinase inhibitors (TKIs) (1,2).